Literature DB >> 34374198

Serum syndecan-4 is associated with nonalcoholic fatty liver disease.

Shu Jing Xia1,2, Li Zhong Tang3, Wen Hua Li4, Zhao Shan Xu1, Li Li Zhang2, Feng Gan Cheng2, Hong Xia Chen1, Zi Hua Wang2, Yu Cheng Luo5, An Na Dai6, Jian Gao Fan7.   

Abstract

OBJECTIVES: The accelerated shedding of extracellular domains of syndecan-4 (SDC4) is associated with central obesity and insulin resistance, while the association between serum SDC4 and nonalcoholic fatty liver disease (NAFLD) is unknown. We aimed to examine the association between SDC4 and NAFLD.
METHODS: Adults undergoing a health examination from 1 June 2019 to 31 December 2019 were enrolled. A diagnosis of NAFLD was made with an abdominal ultrasound. Logistic regression models and the receiver operating characteristic (ROC) curves were used to evaluate the role of SDC4 in predicting NAFLD.
RESULTS: In total, 533 eligible participants were finally enrolled, among them 157 (29.46%) had NAFLD. The proportion of patients with NAFLD increased with the increasing quartiles of serum SDC4. With the increase of serum SDC4 levels, metabolic features including waist circumference, serum triglyceride, total cholesterol, fasting blood glucose, fasting insulin and homeostasis model assessment of insulin resistance were significantly increased. SDC4 was an independent factor for NAFLD (odds ratio 1.963, 95% confidence interval [CI] 1.628-2.367, P < 0.001). The area under the ROC curve of SDC4 for predicting NAFLD was 0.934 (95% CI 0.910-0.959). The optimal cut-off value was 6.575 ng/mL at Youden's index of 0.767. SDC4 had the highest diagnostic sensitivity (84.1%), positive predictive value (82.5%), negative predictive value (93.3%) and positive likelihood ratio (11.356) among all the variables.
CONCLUSIONS: Elevated serum SDC4 level is associated with metabolic disorders and the prevalence of NAFLD among general population. Serum SDC4 may serve as a biomarker of NAFLD.
© 2021 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  diagnosis; metabolic risk factors; nonalcoholic fatty liver disease; syndecan-4

Mesh:

Substances:

Year:  2021        PMID: 34374198     DOI: 10.1111/1751-2980.13037

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  2 in total

1.  SPOCK1 Promotes the Development of Hepatocellular Carcinoma.

Authors:  Lóránd Váncza; Katalin Karászi; Bálint Péterfia; Lilla Turiák; Katalin Dezső; Anna Sebestyén; Andrea Reszegi; Gábor Petővári; András Kiss; Zsuzsanna Schaff; Kornélia Baghy; Ilona Kovalszky
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

2.  High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma.

Authors:  Yufei Zhu; Dijie Zheng; Linhan Lei; Kun Cai; Huahua Xie; Jian Zheng; Chao Yu
Journal:  BMC Cancer       Date:  2022-10-05       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.